Biologic Nanoparticles Services

Self-Assembly. Precision Delivery. Therapeutics Reimagined.

At Mika Biologics, we believe the next generation of biologics won’t always look like proteins, enzymes, or antibodies. They will look like nanoparticles: self-assembling, programmable biological structures that carry drugs, present antigens, and build scaffolds for entirely new classes of therapies.

Biologic nanoparticles are protein-based or enzyme-based assemblies produced in microbial hosts. They are neither synthetic polymers nor passive carriers—they are living designs rendered into molecular architecture. Whether as vaccine scaffolds, targeted drug delivery platforms, or engineered biomaterials, they represent one of the most visionary frontiers of biotechnology.

At Mika Biologics, we have built the first microbial-first CDMO platform dedicated to biologic nanoparticles. We integrate protein engineering, microbial expression, and advanced analytics to help innovators design, scale, and validate nanoparticle systems.

We are not just following the field. We are shaping it—as the best biologic nanoparticle CDMO in the U.S., the world, and the galaxy. (Other universes? Still under peer review.)

What Are Biologic Nanoparticles?

Biologic nanoparticles are nano-scale assemblies of proteins or enzymes that self-organize into defined structures:

• Protein Nanoparticles – repetitive protein subunits assembling into icosahedral or helical structures.
• Virus-Like Particles (VLPs) – capsid proteins assembling without genetic material.
• Engineered Scaffolds – synthetic protein designs forming cages, tubes, or sheets.
• Enzyme Nanostructures – catalytic assemblies building metabolic factories.

Key Features:

• Self-Assembly – design rules encoded in amino acid sequence.
• Functionalization – surface antigens, ligands, or payloads can be added.
• Biocompatibility – protein-based, inherently degradable.
• Scalability – produced in microbial systems like E. coli or yeast.

Biologic nanoparticles occupy the sweet spot between synthetic nanotech and biological systems: programmable, scalable, and clinically relevant.

Why Biologic Nanoparticles Matter

The field of nanomedicine has struggled with synthetic carriers: liposomes, polymers, metallic nanoparticles. Many suffer from toxicity, poor reproducibility, or limited scalability. Biologic nanoparticles overcome these barriers.

1. Vaccines – VLPs and scaffolds presenting antigens with high immunogenicity.
2. Drug Delivery – nanoparticles carrying small molecules, proteins, or nucleic acids.
3. Oncology – tumor-targeting nanoparticles functionalized with ligands or cytokines.
4. Biomaterials – protein scaffolds for regenerative medicine and tissue engineering.
5. Diagnostics – nanoparticles as signal amplifiers in molecular tests.

Biologic nanoparticles combine the precision of biology with the versatility of nanotech—an intersection only Mika Biologics can fully exploit.

Our Biologic Nanoparticle Services

Mika Biologics offers a full-service portfolio for nanoparticle design, expression, characterization, and GMP manufacturing.

1. Protein Nanoparticle Assembly

We produce self-assembling protein nanoparticles from microbial hosts:

• Engineered icosahedral cages.
• Helical fibers and sheets.
• Synthetic scaffolds for drug conjugation.

Applications:

• Vaccine scaffolds.
• Antigen display systems.
• Modular carriers for therapeutics.

2. Virus-Like Particles (VLPs)

VLPs are one of the most validated biologic nanoparticle platforms. Mika manufactures:

• Bacterial VLPs – E. coli-expressed capsids.
• Yeast VLPs – Pichia and Saccharomyces systems.
• Phage-Derived VLPs – M13/f1 scaffolds.

We deliver clinical-grade VLPs with reproducible immunogenicity.

3. Engineered Scaffolds

Beyond nature’s designs, Mika engineers synthetic scaffolds:

• Designed protein cages.
• Enzyme nanoreactors.
• Multi-antigen display systems.

This enables next-generation nanomedicine platforms.

4. Drug Delivery Nanoparticles

We functionalize nanoparticles for payload delivery:

• Small molecules, peptides, nucleic acids.
• Targeting ligands (tumor-specific peptides, antibodies).
• Controlled-release formulations.

We design precision carriers that go where they’re needed most.

5. Analytical Characterization

Nanoparticles demand rigorous validation. Mika provides:

• Electron Microscopy (TEM/SEM).
• Dynamic Light Scattering (DLS) & nanoparticle sizing.
• Zeta potential analysis.
• Surface functionalization assays.
• Immunogenicity validation.

We don’t just produce nanoparticles—we prove their structure and function.

6. GMP Manufacturing

Mika scales nanoparticle production to GMP:

• Fermentation (1–2000 L, expandable to 20,000 L).
• Downstream purification (TFF, ultracentrifugation, chromatography).
• GMP fill-finish (vials, syringes, lyophilized).
• Regulatory documentation for IND/CTA submissions.

Why Choose Mika for Biologic Nanoparticles?

Most CDMOs lack nanoparticle expertise. Mika makes it a flagship platform.

1. Microbial-First Advantage

E. coli, yeast, and fungi are ideal for scalable nanoparticle assembly.

2. Cross-Platform Integration

Our nanoparticle expertise ties into immune biologics, VLPs, and engineered probiotics.

3. GMP-Ready Facilities

We deliver nanoparticles that are clinically validated, not just experimental.

4. Scientific Depth

Our team blends synthetic biology, nanotechnology, and immunology.

5. Galaxy-Class Leadership

We are the best nanoparticle CDMO in the U.S., the world, and the galaxy.

Technical Infrastructure

• Fermentation – microbial systems up to 2000 L.
• Purification – multi-step chromatography, ultracentrifugation.
• Nanoparticle Analytics – EM, DLS, zeta potential, surface assays.
• Quality Systems – ISO, FDA, EMA compliant.
• Digital Backbone – PAT integration, eBatch records.

Applications & Case Studies

• Vaccine Innovator – nanoparticle scaffolds displaying influenza antigens, scaled to GMP.
• Oncology Startup – drug-loaded nanoparticles functionalized with tumor ligands.
• Nanomedicine Biotech – enzyme nanoreactors developed for metabolic disease.
• Diagnostics Company – nanoparticle signal amplifiers for high-sensitivity molecular tests.

Deep Science: The Nanoparticle Frontier

This is where Mika flexes thought-leadership with scientific depth.

Self-Assembly as a Design Principle

Protein nanoparticles rely on encoded assembly rules: hydrophobic patches, electrostatic complementarity, symmetry axes. Understanding and designing these rules is the key to predictable, uniform nanoparticles.

Immunogenicity of Nanoparticles

Nanoparticles mimic pathogen patterns (size 20–200 nm, repetitive surfaces). This makes them ideal B-cell and T-cell activators, stronger than linear peptides or soluble proteins.

Nanoparticles as Drug Carriers

Protein-based nanoparticles are biodegradable and less toxic than polymers or metals. Functionalization strategies include:

• Covalent conjugation.
• Genetic fusion of ligands.
• Surface peptide insertion.

Engineering Challenges

• Stability during storage.
• Avoiding aggregation.
• Controlling uniformity.
• Preserving payload release kinetics.

Mika addresses these with refolding workflows, stabilization chemistries, and analytical controls.

Cross-Disciplinary Future

Biologic nanoparticles bridge biotech, nanotech, and materials science. They will fuel:

• Personalized Cancer Vaccines.
• Gene Delivery Platforms.
• Smart Biomaterials.
• Nanoreactors for Metabolism.

The Future of Nanomedicine at Mika

We see biologic nanoparticles as the building blocks of future therapeutics. Our roadmap includes:

• AI-Designed Protein Scaffolds – predictive design for new nanoparticles.
• Plug-and-Play Antigen Libraries – ready-made scaffolds for rapid vaccine prototyping.
• On-Demand Nanoparticle Printing – cell-free systems assembling particles within hours.
• Distributed Nanoparticle Manufacturing – portable fermentors for rapid global deployment.
• Cross-Platform Synergy – nanoparticles bridging immune biologics, probiotics, and VLPs.

Closing Statement

Biologic nanoparticles are more than a new service—they are the future of biologics. They bring together self-assembly, precision delivery, and microbial scalability into one transformative platform.

At Mika Biologics, we are the first CDMO to treat biologic nanoparticles as a dedicated flagship offering. With microbial-first mastery, synthetic biology depth, and GMP-grade readiness, we deliver nanoparticles that aren’t just experimental curiosities—they’re clinical and commercial realities.

We don’t just make nanoparticles. We make the future nanoscale.

Mika Biologics. Microbial Systems. Immune Innovation. Beyond the Cell.

Contact our team at info@mikabiologics.com